ASX Announcements
Application for quotation of securities - OCC
Appendix 2A (Application for Quotation of Securities)
Orthocell Webinar Presentation
Company Presentation
Web Casts
Market Sensitive
Appendix 4D & Half-Year Financial Report
Half Yearly Report, Half Year Audit Review, Half Year Directors' Statement, Half Year Accounts, Half Year Directors' Report
Remplir FDA Application submitted for US$84M Thai Market
Progress Report
December 2024
Perth’s billionaire set is piling into this little-known medtech
The value of West Australian nerve repair biotech Orthocell has doubled since September as it beefs up its shareholder bases and prepares to break into the US.
October 2024
ReNerve kicks off IPO roadshow, points to market darling Orthocell
ReNerve reckons its NervAlign Nerve Cuff is a lower cost, more effective and easier to use treatment for Peripheral Nerve Injury (PNI).
May 2019
Bell Potter launches placement for Orthocell
ASX-listed regenerative medicine company Orthocell is seeking to raise $10 million in a placement of new shares to investors.
January 2016
Biotech stocks to get the heart racing … or slowing
Notoriously volatile and tricky to pick, biotechnology stocks gave nimble investors plenty of opportunity to outperform blue chips in 2015 and are set to provide some wild rides in 2016 too.
September 2014
Patent success a good sign for Orthocell
From an operational sense, Orthocell has been quick to slip into gear after only listing on the ASX in August. And Foster Stockbroking likes the look of Orthocell, attributing a speculative “buy” recommendation to the stock.
July 2014
Eight stocks to watch
We name some recently listed stocks that analysts The Australian Financial Review spoke to suggested are worth a closer look.